Guardian Partners Inc. Purchases 18,060 Shares of Pfizer Inc. $PFE

Key Points

• Guardian Partners Inc. has increased its stake in Pfizer Inc. by 14%, now holding 146,711 shares valued at approximately $3.7 million.
• Pfizer reported earnings of $0.78 per share, surpassing the consensus estimate of $0.58, and generated $14.65 billion in revenue for the quarter, exceeding expectations of $13.43 billion.
• The company announced a quarterly dividend of $0.43, resulting in an annualized dividend of $1.72 and a yield of 6.9% for shareholders of record.

Guardian Partners Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 146,711 shares of the biopharmaceutical company's stock after buying an additional 18,060 shares during the period. Guardian Partners Inc.'s holdings in Pfizer were worth $3,718,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bessemer Group Inc. increased its holdings in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK raised its position in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after purchasing an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer during the first quarter valued at $8,283,000. Alta Advisers Ltd grew its stake in Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after acquiring an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC grew its stake in Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after acquiring an additional 10,051 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on PFE shares. Morgan Stanley raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. HSBC cut their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

PFE stock traded down $0.33 during trading on Monday, hitting $24.55. 49,188,016 shares of the company's stock traded hands, compared to its average volume of 34,669,424. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The business has a fifty day simple moving average of $24.85 and a 200 day simple moving average of $24.32. The stock has a market capitalization of $139.56 billion, a price-to-earnings ratio of 13.06, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.